secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001628280-26-001459
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm Pharma Q4 2025 IMCIVREE revenue ~$57M (+11% QoQ); FY2025 ~$194M (+50% YoY)
--------------------------------------------------------------------------------

- Q4 2025 net product revenue ~$57M, up 11% sequentially from Q3 2025.
- FY2025 net product revenue ~$194M, a ~50% increase from $130M in FY2024.
- U.S. sales contributed ~68% of Q4 and ~69% of full-year 2025 revenues.
- FDA PDUFA goal date of March 20, 2026 for setmelanotide sNDA in acquired hypothalamic obesity.
- Topline data from Phase 3 EMANATE trial in MC4R pathway diseases expected in Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000162828026001459/0001628280-26-001459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000162828026001459/rytm-20260109.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-001459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer